Literature DB >> 1790430

High frequency of antithrombin 3 and protein C deficiency following autologous bone marrow transplantation for lymphoma.

B Gordon1, W Haire, A Kessinger, M Duggan, J Armitage.   

Abstract

To investigate the possibility that a hypercoagulable state develops during autologous bone marrow transplantation (BMT), we measured levels of circulating natural anticoagulants and fibrinolytic proteins before and weekly during the hospital course of 18 patients undergoing autologous BMT for Hodgkin's and non-Hodgkin's lymphoma. Patients received either weekly (standard dose group) or daily (high dose group) vitamin K supplements with their total parenteral nutrition. By day 14 there had been a significant drop in protein C activity (mean of 95% of normal to 52%), protein C antigen (mean of 105% of normal to 70%), and antithrombin 3 activity (111% of normal to 83%), and an increase in fibrinogen (471-621 mg/dl) and tissue plasminogen activator (6.9-13.8 ng/ml). No changes were seen in free or total protein S, plasminogen activator inhibitor, prothrombin time or partial thromboplastin time. The decreases in protein C and antithrombin 3 persisted through day 28 after transplantation. The drop in protein C correlated strongly with decrease in serum albumin, suggesting impaired synthesis of these proteins by the liver. No differences were seen in any of these parameters between the standard and high dose groups. Deficiencies in anticoagulant proteins antithrombin 3 and protein C and a rise in fibrinogen without a concomitant improvement in fibrinolytic variables create a potentially hypercoagulable state which may contribute to the thrombotic complications of autologous BMT.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1790430

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  6 in total

1.  Endovascular stenting for the management of port-a-cath associated superior vena cava syndrome.

Authors:  Vasiliki Kostopoulou; Marinos L Tsiatas; Dimitrios A Kelekis; Meletios-Athanasios Dimopoulos; Christos A Papadimitriou
Journal:  Emerg Radiol       Date:  2008-03-06

2.  Catheter-Related Thrombosis in Patients with Lymphoma or Myeloma Undergoing Autologous Stem Cell Transplantation.

Authors:  Livia Hegerova; Adam Bachan; Qing Cao; Huong X Vu; John Rogosheske; Mark T Reding; Claudio G Brunstein; Mukta Arora; Celalettin Ustun; Gregory M Vercellotti; Veronika Bachanova
Journal:  Biol Blood Marrow Transplant       Date:  2018-07-25       Impact factor: 5.742

3.  A novel protein C inhibitor gene mutation in pediatric stroke patients after bone marrow transplantation.

Authors:  Didem Torun; Gülhis Deda; Mehmet Ertem; Zümrüt Uysal; Erkan Yılmaz; Nejat Akar
Journal:  Mol Biol Rep       Date:  2013-05-14       Impact factor: 2.316

4.  Coordinated responses of natural anticoagulants to allogeneic stem cell transplantation and acute GVHD - A longitudinal study.

Authors:  Beata Przybyla; Anne Pinomäki; Jari Petäjä; Lotta Joutsi-Korhonen; Karin Strandberg; Andreas Hillarp; Ann-Kristin Öhlin; Tapani Ruutu; Liisa Volin; Riitta Lassila
Journal:  PLoS One       Date:  2017-12-22       Impact factor: 3.240

Review 5.  Endothelial Dysfunction after Hematopoietic Stem Cell Transplantation: A Review Based on Physiopathology.

Authors:  Giuseppe Milone; Claudia Bellofiore; Salvatore Leotta; Giulio Antonio Milone; Alessandra Cupri; Andrea Duminuco; Bruno Garibaldi; Giuseppe Palumbo
Journal:  J Clin Med       Date:  2022-01-26       Impact factor: 4.241

6.  Early predictors of mortality in children with pulmonary complications after haematopoietic stem cell transplantation.

Authors:  Yu Hyeon Choi; Hyung Joo Jeong; Hong Yul An; You Sun Kim; Eui Jun Lee; Bongjin Lee; Hyoung Jin Kang; Hee Young Shin; June Dong Park
Journal:  Pediatr Transplant       Date:  2017-10-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.